Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 14/20 | 0.54 |
| ▸ | GSK3B | P49841 | 13/20 | 0.54 |
| ▸ | SRC | P12931 | 9/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833901 | 0.84 | AURKA (0.49) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL12431000 | 0.79 | AURKA (0.42) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL5071901 | 0.79 | AURKA (0.43) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL12430988 | 0.77 | AURKA (0.54) | AURKAAURKBGSK3BSRCAURKC | |
| SCHEMBL12430714 | 0.73 | AURKA (0.70) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL5069317 | 0.73 | LRRK2 (0.40) | AURKAAURKBGSK3BSRCAURKC | |
| SCHEMBL12102747 | 0.71 | AURKA (0.68) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL12430446 | 0.71 | AURKA (1.00) | AURKAAURKBGSK3BSRCAURKC | |
| SCHEMBL12102875 | 0.69 | AURKA (0.65) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL5482113 | 0.69 | IGF1R (0.42) | AURKAAURKBGSK3BSRCNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345928-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2007-02-14 | — | — | EP | claimed |
| US-20040167141-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-08-26 | — | — | US | claimed |
| US-20030022885-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-30 | — | — | US | claimed |
| US-20140187772-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-20140187772-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-20130096128-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-04-18 | — | — | US | disclosed |
| US-20130096128-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-04-18 | — | — | US | disclosed |
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167141-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885AURKB 5/4885GSK3B 3/4885 |
| US-20030022885-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | AURKA 2/4885AURKB 5/4885GSK3B 3/4885 |
| US-20130096128-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | AURKA 2/4885AURKB 5/4885GSK3B 4/4885 |
| US-20140187772-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | AURKA 2/4885AURKB 5/4885GSK3B 4/4885 |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | AURKA 2/4885AURKB 5/4885GSK3B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.